FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. PMID 38150256 · JAMA Netw Open · 2023-Dec-01 The trial is a randomized, placebo-controlled study with a drug intervention and reports time-to-event results (hazard ratios) for prostate cancer incidence. However, the primary endpoint is a safety outcome (risk of prostate cancer) in the context of testosterone replacement therapy, not an efficacy endpoint (like OS, PFS) for treating an existing malignancy. The trial is oncology-related but does not test a drug for cancer treatment efficacy. The phase is also not explicitly stated, preventing confirmation as a definitive Phase III trial. Therefore, it does not meet the criterion for a primary or key secondary time-to-event efficacy endpoint in an oncology drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary Care Utilization and Cardiovascular Screening in Adult Survivors of Childhood Cancer. PMID 38091040 · JAMA Netw Open · 2023-Dec-01 The record is a cross-sectional analysis of healthcare utilization among adult survivors of childhood cancer. While it involves participants from a randomized trial, the analyzed study is not a drug efficacy trial, lacks a time-to-event efficacy endpoint, and does not meet the core criteria for inclusion in the specified Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 38051531 · JAMA Netw Open · 2023-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. PMID 38048133 · JAMA Netw Open · 2023-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. PMID 38040420 · J Immunother Cancer · 2023-Dec-01 The study is an original RCT with a drug intervention and an OS endpoint, but the trial phase is not established as Phase III/IIIb or Phase II/III from the given text, and its primary objectives were safety and a biomarker, not definitive efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. PMID 37883073 · JAMA Oncol · 2023-Dec-01 The study is a randomized, Phase 3 oncology trial with a drug intervention, but its primary endpoint is a safety/toxicity measure (neutropenia), not a time-to-event efficacy endpoint. The abstract does not report results for OS, PFS, DFS, or any other time-to-event outcome. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. PMID 37878305 · JAMA Surg · 2023-Dec-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. PMID 37824137 · JAMA Oncol · 2023-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cocoa Extract Supplementation and Risk of Type 2 Diabetes: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Randomized Clinical Trial. PMID 37816167 · Diabetes Care · 2023-Dec-01 The record describes a randomized clinical trial evaluating cocoa extract supplementation for the prevention of cardiovascular disease and cancer, but the primary endpoint reported in this abstract is incident type 2 diabetes, not a cancer-specific efficacy endpoint. The intervention is a dietary supplement (cocoa extract), not a drug. Therefore, it does not meet the criteria for an oncology trial with a drug intervention and a time-to-event cancer efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better? PMID 37800589 · Int J Surg · 2023-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. PMID 37656930 · J Clin Oncol · 2023-Dec-01 Study meets criteria for oncology, human, randomized, original result, and drug intervention (chemotherapy), but lacks a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and associated survival analysis (Kaplan-Meier, HR). The primary outcomes are relative dose intensity and pathologic complete response, which are not time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance). PMID 37651160 · Cancer · 2023-Dec-01 The record is a prospective cohort study nested within a randomized trial, analyzing the association of physical activity (non-drug intervention) with overall survival after tumor recurrence. While the parent trial (CALGB/SWOG 80702) is a randomized adjuvant chemotherapy trial (drug intervention), this specific report is not a report of a drug-containing intervention's efficacy; it is a secondary analysis of a lifestyle factor. It also does not explicitly confirm the parent trial's phase as Phase III/IIIb in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Novel Biomaterial Containing Gelatin, Manuka Honey, and Hydroxyapatite Enhanced Secondary Intention Healing Versus Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities-A Randomized Controlled Trial: Pilot Study. PMID 37647156 · Dermatol Surg · 2023-Dec-01 The study is a randomized controlled trial in oncology (skin neoplasms) but compares a non-drug biomaterial to standard wound healing. The primary endpoint is time to re-epithelialization, which is not a standard oncology efficacy time-to-event endpoint (e.g., OS, PFS, DFS) requiring Kaplan-Meier or HR analysis. Therefore, it fails the drug intervention and time-to-event criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. PMID 37535876 · J Clin Oncol · 2023-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617. PMID 37343707 · Int J Radiat Oncol Biol Phys · 2023-Dec-01 The record describes an analytical sub-study of a randomized trial (RTOG 0617) focusing on machine learning to select radiation dose-volume constraints. While it is oncology, human, randomized, and includes OS as a time-to-event endpoint, it fails two key eligibility criteria: 1) The trial phase is not explicitly stated in the provided metadata (it is likely Phase III but not confirmed), and 2) The primary intervention under analysis is a radiation therapy planning parameter, not a drug-containing intervention. The abstract reports results on model performance for predicting OS based on dose features, not the efficacy of a drug regimen. Therefore, it is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| China special issue on gastrointestinal tumors-Regulatory-immunoscore-A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer. PMID 37085990 · Int J Cancer · 2023-Dec-01 The record is an original study on a novel prognostic biomarker (regulatory-Immunoscore) in colorectal cancer. While it uses data from a randomized dataset and analyzes the interaction of chemotherapy with the biomarker, the primary focus is biomarker validation, not the report of a Phase III/IIIb or Phase II/III drug trial's primary/secondary efficacy results. The phase of the underlying trial is not specified in the metadata, and the study is not a primary report of a trial comparing drug interventions. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study. PMID 36891751 · Haematologica · 2023-Dec-01 The study is a randomized, prospective, human oncology trial with time-to-event endpoints (OS, relapse). However, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, or deterministic review), and the intervention is a multi-drug regimen but the primary focus is on CNS involvement; the drug-specific intervention is not the primary subject of this analysis, making drug_intervention not clearly established as a drug-containing intervention for the efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments. PMID 38557561 · Eur J Cancer · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol. PMID 38464470 · Neurosurg Pract · 2023-Dec 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Restrictive versus goal-directed fluid replacement strategy in ovarian cancer cytoreductive surgery (RiGoROCS): A randomised controlled trial. PMID 38343671 · Indian J Anaesth · 2023-Dec The study is an original randomized controlled trial in ovarian cancer, but it evaluates fluid management strategies (goal-directed fluid therapy vs. restrictive) for cytoreductive surgery, which is a non-drug (procedure/supportive care) intervention. The primary endpoint is hospital length of stay, a non-time-to-event outcome. No time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR is reported. Phase is not specified as definitive (e.g., Phase III), and it is a perioperative supportive care study, not a drug intervention trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. PMID 38320501 · NEJM Evid · 2023-Dec While the trial (EMBARK) is a randomized Phase III oncology study with a drug intervention and includes time-to-event analyses, the primary/key endpoint of this specific report is patient-reported quality of life outcomes (TTFD/TTCD for pain and QoL), not a primary/key oncologic efficacy endpoint like OS or PFS. The abstract explicitly states the key endpoint was QoL deterioration. Therefore, it does not meet the criterion for a primary/key time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| LONG-TERM OUTCOMES OF SENTINEL LYMPH NODE BIOPSY VERSUS LYMPH NODE OBSERVATION IN MELANOMA PATIENTS. PMID 38155145 · Probl Radiac Med Radiobiol · 2023-Dec The record is a randomized, oncology trial with primary time-to-event results, but it does not meet the eligibility criteria because it lacks an explicit Phase III/IIIb or Phase II/III designation and the intervention being compared is a surgical procedure (sentinel lymph node biopsy) rather than a drug-containing regimen. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial. PMID 38130050 · Intern Med J · 2023-Dec The report is a cost-effectiveness analysis of a trial delivery model within an oncology trial. It is not a report of a drug intervention's efficacy on a time-to-event endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities. PMID 38125671 · J Clin Aesthet Dermatol · 2023-Dec The study is a randomized, drug-intervention oncology trial (including Phase III), but the reported outcomes are patient satisfaction and acceptability metrics. These are not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report type is 'secondary' (or quality_of_life), making it ineligible for this cohort which requires a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The short-term effect of glucosamine-sulfate, nonanimal chondroitin-sulfate, and S-adenosylmethionine combination on ultrasonography findings, inflammation, pain, and functionality in patients with knee osteoarthritis: A pilot, double-blind, randomized, placebo-controlled clinical trial. PMID 38125054 · Arch Rheumatol · 2023-Dec The study is a randomized, double-blind, placebo-controlled trial investigating glucosamine-sulfate, chondroitin-sulfate, and S-adenosylmethionine for knee osteoarthritis. It is not an oncology study, is a pilot (likely Phase II equivalent, not definitive Phase III), and reports clinical, inflammatory, and ultrasound outcomes with no time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study. PMID 38085706 · PLoS Med · 2023-Dec The record is an observational study analyzing the design of randomized clinical trials, not an original report of a clinical trial's efficacy results. It does not provide time-to-event outcome data for a specific drug intervention. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preventive effect of aspirin on peripherally inserted central catheter-related vein thrombosis in patients with malignant tumors. PMID 38072566 · J Vasc Nurs · 2023-Dec The study is a randomized, placebo-controlled trial in oncology patients with a drug intervention, but its primary efficacy endpoint is the prevention of a catheter-related complication (venous thrombosis), not a time-to-event efficacy endpoint for the cancer (e.g., overall survival, progression-free survival). It does not meet the required endpoint criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. PMID 38072514 · Ann Oncol · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects of a return to work program on the health and barriers to returning to work in head and neck cancer patients: A randomized controlled trial. PMID 38059206 · Asia Pac J Oncol Nurs · 2023-Dec The study is a randomized controlled trial in head and neck cancer patients, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified), does not have a drug-containing intervention (intervention is a return-to-work program), and does not have a time-to-event efficacy endpoint (outcomes are patient-reported functional and psychosocial measures). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma. PMID 38046900 · Int J Surg Protoc · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. PMID 38039992 · Lancet Oncol · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. PMID 38017340 · J Neurooncol · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. PMID 37985501 · J Cancer Res Clin Oncol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men. PMID 37971326 · Acta Oncol · 2023-Dec The study is a randomized trial analyzing the association between testosterone replacement therapy (a hormone therapy) and prostate cancer incidence/mortality. However, it is a screening cohort study (Finnish Randomized Study of Screening for Prostate Cancer), not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention for cancer treatment. The drug (testosterone) is evaluated for safety/association, not as a therapeutic intervention with a primary time-to-event efficacy endpoint in an oncology treatment context. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative cerebrospinal fluid leakage and residual tumors in endoscopic transsphenoidal surgery for pituitary adenoma: risk analysis and nomogram development. PMID 37966528 · Acta Neurochir (Wien) · 2023-Dec The record is a retrospective analysis of surgical outcomes for pituitary adenomas, which is oncology-related and human. It uses random assignment for model validation but is not a drug intervention trial, does not report a time-to-event efficacy endpoint, and is not a Phase III/IIIb or Phase II/III trial. Therefore, it is ineligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Couples' skills training intervention in young breast cancer patients with fear of cancer recurrence: A randomized controlled trial. PMID 37952275 · Eur J Oncol Nurs · 2023-Dec The study is a randomized trial in oncology with original results, but it lacks a drug intervention and a time-to-event efficacy endpoint (e.g., OS, PFS, DFS), focusing instead on psychosocial outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. PMID 37949086 · Lancet Oncol · 2023-Dec The study is a randomized, phase 2/3 trial of an HPV vaccine with a drug intervention, but the primary endpoint is immunogenicity (geometric mean titers), not a time-to-event efficacy endpoint (e.g., overall survival, progression-free survival). No Kaplan-Meier analysis or hazard ratio for a time-to-event outcome is reported. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study). PMID 37947242 · Clin Respir J · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan. PMID 37934081 · Acta Oncol · 2023-Dec The record is a Phase III randomized trial in oncology with a drug intervention and is an original result report. However, the provided metadata (title, publication types, mesh terms, deterministic review) does not contain any explicit signal of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. Without this signal, eligibility cannot be confirmed. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. PMID 37931445 · Lung Cancer · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. PMID 37922770 · Lung Cancer · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. PMID 37914801 · Br J Cancer · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension. PMID 37905356 · Clin Transl Sci · 2023-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low-impact laparoscopy in colorectal resection-A multicentric randomised trial comparing low-pressure pneumoperitoneum plus microsurgery versus low-pressure pneumoperitoneum alone: The PAROS II trial. PMID 37897108 · Colorectal Dis · 2023-Dec 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Physical exercise in patients with testicular cancer treated with bleomycin, etoposide and cisplatin chemotherapy: pulmonary and vascular endothelial function-an exploratory analysis. PMID 37889308 · J Cancer Res Clin Oncol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. PMID 37882432 · Future Oncol · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Inflammatory markers in serum and placenta in a randomized controlled trial of group prenatal care. PMID 37875178 · Am J Obstet Gynecol MFM · 2023-Dec The record is a randomized controlled trial of group prenatal care (a non-drug intervention) in obstetrics, assessing inflammation biomarkers and placental lesions as endpoints. It does not meet any of the core oncology, drug intervention, or time-to-event efficacy criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a guided online primary care intervention for fear of cancer recurrence: A randomised controlled trial. PMID 37850876 · Psychooncology · 2023-Dec The record describes a randomized trial in cancer survivors, but the primary endpoint is a change in a psychological score (fear of cancer recurrence severity) at 6 months, not a time-to-event outcome. Additionally, the intervention is an online psychological therapy, not a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. PMID 37833178 · Eur Urol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Axillary Treatment and Chronic Breast Cancer-Related Lymphedema: Implications for Prospective Surveillance and Intervention From a Randomized Controlled Trial. PMID 37816208 · JCO Oncol Pract · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |